Healthcare Industry News: spinal cord injury
News Release - October 23, 2018
CavoGene LifeSciences Licenses Novel Gene Therapy for CNS DisordersAgreement with University California San Diego Provides License for Production of SynCav1, an Investigational Novel Gene Therapy for Treatment of Alzheimer's Disease and Amyotrophic Lateral Sclerosis
GLEN BURNIE, Md., Oct. 23, 2018 -- (Healthcare Sales & Marketing Network) -- CavoGene LifeSciences has announced that it has licensed a novel investigational gene therapy for patients with neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), traumatic brain and spinal cord injury, and age-related cognitive decline. Currently, there is a large unmet medical need for these life-threatening conditions.
CavoGene has licensed the rights for the development and commercialization of SynCav1 from the University California San Diego (UC San Diego). SynCav1 is a novel gene therapy intervention that restores and augments pro-growth signaling, axonal and dendritic growth, and formation of new functional synapses in animal models.
SynCav1 was developed by Brian P. Head, Ph.D., a Veterans Affairs' research scientist and associate adjunct professor in UC San Diego School of Medicine's Department of Anesthesiology, and co-inventors, Hemal H. Patel, Ph.D., professor and vice-chair for research; Piyush M. Patel, M.D., professor; and David M. Roth, M.D., Ph.D., professor. The data demonstrate that SynCav1 improves motor function, maintains body weight and extends survival in ALS rodent models, increases structural and functional neuroplasticity, and improves learning and memory in aged mice and in an AD mouse model. SynCav1 represents a new paradigm that uses a single genetic intervention, namely neuron-targeted Caveolin-1 overexpression (e.g., SynCav1), to re-establish polarized plasma membrane signaling microdomains (termed membrane/lipid rafts, MLRs), with improved neurotrophin and synaptic signaling and enhanced neuroregeneration and innervation. Clinically, SynCav1 has the therapeutic potential to improve cognitive function and to improve the quality of life for those afflicted with neurodegenerative disorders.
"Cav-1 is a neuronal cell membrane scaffolding protein, analogous to a coat hanger in one's closet," said Dr. Head. "By recruiting and organizing synaptic receptors and associated signaling components together in close proximity, Cav-1 allows for the enhancement of functional synapses and neuroplasticity. In addition, we believe that this novel gene therapy could also work in combination to enhance the efficacy of compounds that activate synaptic signaling complexes."
CavoGene has contracted with CSSi LifeSciences to manage the preclinical, GMP, regulatory, and clinical development of SynCav1. Jim Sergi, President of CSSi LifeSciences, stated, "We are excited by the opportunity to leverage our experience and subject matter expertise to advance the commercial development of this potential disease modifying therapy."
For more about CavoGene LifeSciences and its neurodegenerative disease research, please visit www.cavogene.com.
About CavoGene LifeSciences
CavoGene LifeSciences was founded with a mission to develop effective therapies for neurodegenerative diseases, such as Alzheimer's disease and ALS. CavoGene's innovative gene therapy treatment targeting Caveolin-1 has the potential to be a major breakthrough in the treatment of patients suffering from life-threatening neurodegenerative diseases.
About UC San Diego
UC San Diego was founded in 1960 as a forward-thinking research institution for graduate and undergraduate study. Scripps Institution of Oceanography, established in 1903 and now a division of the university, served as a catalyst for UC San Diego's initial growth. Today, our campus has grown to encompass six undergraduate residential colleges, five academic divisions - Arts & Humanities, Biological Sciences, Jacobs School of Engineering, Physical Sciences and Social Sciences - three graduate schools, a medical school and a school of pharmacy.
About CSSi LifeSciences
CSSi LifeSciences provides fully integrated regulatory and clinical services to support the entire product lifecycle, from discovery to commercialization, for pharmaceutical and medical device companies. With global expertise, CSSi LifeSciences has been a key partner in the development of more than 500 drugs, biologics, medical devices, and in-vitro diagnostics. The company's headquarters is located in Baltimore, MD, with additional offices in San Francisco, California and Hyderabad, India. For more information, visit: www.cssilifesciences.com.
Source: CavoGene LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.